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Unrest in Myanmar in August 2017 resulted in the movement of over 700,000 Rohingya ref-
ugees to overcrowded camps in Cox’s Bazar, Bangladesh. A large outbreak of diphtheria
subsequently began in this population.
Methods and findings
Data were collected during mass vaccination campaigns (MVCs), contact tracing activities,
and from 9 Diphtheria Treatment Centers (DTCs) operated by national and international
organizations. These data were used to describe the epidemiological and clinical features
and the control measures to prevent transmission, during the first 2 years of the outbreak.
Between November 10, 2017 and November 9, 2019, 7,064 cases were reported: 285
(4.0%) laboratory-confirmed, 3,610 (51.1%) probable, and 3,169 (44.9%) suspected cases.
The crude attack rate was 51.5 cases per 10,000 person-years, and epidemic doubling time
was 4.4 days (95% confidence interval [CI] 4.2–4.7) during the exponential growth phase.
The median age was 10 years (range 0–85), and 3,126 (44.3%) were male. The typical
symptoms were sore throat (93.5%), fever (86.0%), pseudomembrane (34.7%), and gross
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cervical lymphadenopathy (GCL; 30.6%). Diphtheria antitoxin (DAT) was administered to
1,062 (89.0%) out of 1,193 eligible patients, with adverse reactions following among 229
(21.6%). There were 45 deaths (case fatality ratio [CFR] 0.6%). Household contacts for
5,702 (80.7%) of 7,064 cases were successfully traced. A total of 41,452 contacts were iden-
tified, of whom 40,364 (97.4%) consented to begin chemoprophylaxis; adherence was
55.0% (N = 22,218) at 3-day follow-up. Unvaccinated household contacts were vaccinated
with 3 doses (with 4-week interval), while a booster dose was administered if the primary vac-
cination schedule had been completed. The proportion of contacts vaccinated was 64.7%
overall. Three MVC rounds were conducted, with administrative coverage varying between
88.5% and 110.4%. Pentavalent vaccine was administered to those aged 6 weeks to 6
years, while tetanus and diphtheria (Td) vaccine was administered to those aged 7 years and
older. Lack of adequate diagnostic capacity to confirm cases was the main limitation, with a
majority of cases unconfirmed and the proportion of true diphtheria cases unknown.
Conclusions
To our knowledge, this is the largest reported diphtheria outbreak in refugee settings. We
observed that high population density, poor living conditions, and fast growth rate were
associated with explosive expansion of the outbreak during the initial exponential growth
phase. Three rounds of mass vaccinations targeting those aged 6 weeks to 14 years were
associated with only modestly reduced transmission, and additional public health measures
were necessary to end the outbreak. This outbreak has a long-lasting tail, with Rt oscillating
at around 1 for an extended period. An adequate global DAT stockpile needs to be main-
tained. All populations must have access to health services and routine vaccination, and this
access must be maintained during humanitarian crises.
Author summary
Why was this study done?
• Following the mass displacement of a highly vulnerable Rohingya population from
Myanmar to Bangladesh in 2017, a large outbreak of diphtheria, a vaccine-preventable
disease, occurred and spread rapidly, eventually lasting over 2 years. A large-scale inter-
national response effort was mounted to respond to the crisis, involving case isolation
and treatment; tracing their close contacts and administering preventive antibiotic treat-
ment; and mass vaccination campaigns (MVCs).
• Few, if any, previous studies have documented the epidemiological, clinical, and public
health response characteristics of large outbreaks of diphtheria among vulnerable popu-
lations. We aim to provide such information to inform future public health response
efforts.
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What did the researchers do and find?
• Between November 2017 and November 2019, 7,064 cases of diphtheria were identified.
Most of the cases were among children, although a larger than expected proportion
occurred among adults. Case fatality was low, with just 45 deaths.
• Symptoms were typical of diphtheria: sore throat (93.5%), fever (86.0%), pseudomem-
brane (34.7%), and gross cervical lymphadenopathy (GCL; 30.6%).
• Diphtheria antitoxin (DAT) was administered to 1,062 (89.0%) out of 1,193 eligible
patients, with adverse reactions following among 229 (21.6%). A total of 41,452 house-
hold contacts were identified, of whom 40,364 (97.4%) consented to chemoprophylactic
antibiotic therapy. An MVC achieved high coverage among the target population.
What do these findings mean?
• High population density, poor living conditions, and fast growth rate caused explosive
expansion of the outbreak during the initial exponential growth phase.
• Three rounds of mass vaccinations targeting children were associated with only modest
reductions in transmission, and additional public health measures were necessary to
end the outbreak.
• Diphtheria outbreaks in refugee settings may have a long-lasting tail and may require
additional public health measures, such as expanded target age groups for vaccination,
to bring to an end. Ensuring laboratory capacity for differential diagnosis in remote
field sites is an important challenge.
Introduction
On August 25, 2017, violence erupted in Rakhine state, Myanmar and resulted in the displace-
ment of approximately 720,000 refugees—mostly stateless Rohingya—from Rakhine state into
the neighboring district of Cox’s Bazar, Bangladesh. Together with previously displaced refu-
gees, the total number of Rohingya in Bangladesh exceeds 930,000 [1].
Most of the recent Rohingya settled in preexisting and expanded camps in Ukhia and
Teknaf areas or among the nearby host population. The speed and scale of displacement cre-
ated a humanitarian emergency. Basic humanitarian services still remain under considerable
strain despite intense efforts by the Bangladesh Government and medical and humanitarian
partners working in the region [2]. The population is vulnerable to many diseases [1–3], and
years of isolation and poor access to health services have resulted in low acquired or vaccine-
derived immunity against a variety of diseases [4], leading to outbreaks of diphtheria, measles,
and hepatitis A in 2017 and mumps and varicella in 2018, in Cox’s Bazar refugee camps [5–8].
Cases of Coronavirus Disease 2019 (COVID-19) have recently been detected in this population
[9].
Diphtheria is a bacterial infection caused by toxigenic strains of Corynebacterium diphther-
iae, primarily causing infection of the mucous membrane of the upper respiratory tract [10].
Local bacterial growth and subsequent tissue death may create a pseudomembrane potentially
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leading to airway obstruction; in severe cases, disseminated toxin may cause myocarditis or
peripheral neuropathy [11,12]. The disease is typically transmitted through respiratory drop-
lets or by direct contact with cutaneous lesions or fomites [11,12]. The incubation period is
typically 2 to 5 days, and the infectious period for respiratory diphtheria is typically 2 to 4
weeks [12]. Diphtheria antitoxin (DAT) treatment is used to neutralize the circulating toxin in
respiratory diphtheria, administered ideally 48 hours post-onset of symptoms [12–14], but due
to the small risk for anaphylaxis [15], a sensitization test is frequently performed prior to
administration. Antibiotic treatment is used to eliminate the bacteria, halt toxin production,
and reduce transmissibility [11,12]. Prophylactic antibiotic treatment coupled with diphtheria
toxoid vaccination should be considered for close contacts [11,12]. The inclusion of a diphthe-
ria vaccine in childhood immunization protocols after World War II has reduced the inci-
dence of diphtheria worldwide [16,17].
In settings where vaccination coverage is low, children under 15 years account for the high-
est proportion of diphtheria cases, but once high vaccination coverage has been achieved for
some time, adolescents and adults account for the majority of cases, due to an absence of, or
waning, immunity [18–21]. Case fatality ratios (CFRs) are 5% to 10%, with a higher CFR
among young children [11,12,22]. Vaccination with at least 3 primary doses of diphtheria–tet-
anus–containing vaccine is recommended for persons aged 0 to 18 years, with at least a
6-month interval between second and third doses [15]. Three diphtheria toxoid–containing
booster doses given after completion of the primary series, at 12 to 23 months, 4 to 7 years,
and 9 to 15 years, is further recommended [15].
Despite a decrease in worldwide incidence, diphtheria outbreaks still occur, particularly
among populations with poor vaccination coverage. Outbreaks in Central and South America,
India and South Asia, Thailand, Laos, and Nigeria have been reported in recent decades
[20,22–28]. In 2017, outbreaks occurred in Yemen, Venezuela, and Indonesia, with an ongoing
outbreak in Haiti [29–32]. However, the Cox’s Bazar outbreak represents the largest outbreak
since the 1990s, when over 140,000 cases were recorded in the Newly Independent States of
the former Soviet Union [33].
On November 10, 2017, Médecins Sans Frontières (MSF) reported a case of suspected diph-
theria in a 30-year-old Rohingya woman from Ukhiya. Additional suspected cases were
reported, and after laboratory confirmation on December 4, 2017, the Bangladesh Ministry of
Health and Family Welfare (MOH&FW) officially declared an outbreak. We describe the epi-
demiological and clinical features of the diphtheria outbreak among Rohingya and the local
host population in Cox’s Bazar district, Bangladesh during the first 2 years of the ongoing out-
break, from November 10, 2017 to November 9, 2019, and the characteristics of the public
health response to the outbreak.
Methods
Population, data source, and case definitions
All suspected cases were referred to 9 Diphtheria Treatment Centers (DTCs), operated by the
Bangladesh Red Crescent, International Organization for Migration, MSF, or Samaritan’s
Purse. DTCs collected daily data for demographic, epidemiological, and clinical characteristics
of cases. Data were collected by field investigators using a standardized case investigation form
which captured detailed sociodemographic characteristics, history of contact with known
cases, and vaccination history. Additionally, close contacts, defined as household members (all
persons sleeping in the same house/tent during the 5 nights prior to disease onset) and any
persons with close contact (less than 1 meter) for a prolonged time (over 1 hour) during the 5
days prior to disease onset, and medical staff exposed to the oral or respiratory secretions of a
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case, were listed on a separate form [34]. Clinical and laboratory results were also recorded. All
data were reported electronically to the World Health Organization’s (WHO) Early Warning,
Alert and Response System (EWARS) for consolidation and cleaning [35]. We extracted case
and contact tracing data for cases with symptom onset from November 10, 2017 to November
9, 2019. Reported cases were classified as suspected, probable, and confirmed cases on clinical
and laboratory information, as per standard WHO and MOH&FW diphtheria surveillance
case definitions:
• Confirmed: case patients reported as positive for toxigenic C. diphtheriae by PCR;
• Probable: case patients with an upper respiratory tract illness with laryngitis or nasopharyn-
gitis or tonsillitis and at least one of the following signs: adherent membrane/pseudomem-
brane or gross cervical lymphadenopathy (GCL); and
• Suspected: any case with a clinical suspicion of diphtheria.
Due to the lack of specific and objectively observable signs and symptoms in the case defini-
tion for suspect cases, the admission, treatment, and reporting of suspect cases was therefore
based on the subjective judgment of the clinician who examined the case.
Clinical management
Patients were triaged upon arrival to the DTC based on disease severity in order to provide
appropriate clinical management. According to the treatment protocol, DAT was to be admin-
istered to eligible patients with probable, clinical diagnosis of respiratory diphtheria, i.e., any-
one presenting with either pseudomembrane or GCL. Further details on the protocol are
reported elsewhere [34]. Owing to its limited global supply [15] and the need for close moni-
toring of patients during its administration, DAT was administered only to patients with
severe disease requiring inpatient admission. DAT-treated patients were monitored closely for
signs of respiratory distress from the development of airway obstruction or aspiration. Cardiac
function was also monitored with ECG for conduction abnormalities and arrhythmias. In
cases of upper airway obstruction, 2 ml of 1:1,000 solution nebulized adrenaline was adminis-
tered hourly as a temporizing measure. Where shock due to heart failure was suspected, ino-
tropes (such as dopamine or adrenaline) were administered.
Complications of diphtheria infection were assessed prior to case resolution (discharge or
death), with long-term follow-up of patients performed up to 30 days post-discharge.
Diagnostics
Material for laboratory diagnostics was obtained either by nasopharyngeal swab or by throat
swab of the edges of the mucosal lesions, with extraction of pieces of membrane, and placed in
Amies transport media. Further details on the protocol are reported elsewhere [34].
Swabs were cultured on Trypticase Soy Agar with 5% sheep blood (TSA+SB) (Thermo
Fisher Scientific, Waltham, Massachusetts, United States of America) and/or Tinsdale agar
(Remel, Lenexa, Kansas, USA) or BD (Franklin Lakes, New Jersey, USA). Isolates were identi-
fied with the API Coryne kit (bioMérieux, Durham, North Carolina, USA). Toxigenicity was
determined by the modified Elek test [36]. Swabs underwent confirmatory laboratory testing
for tox-bearing C. diphtheriae by real-time PCR with a multiplex PCR assay for the diphtheria
toxin gene, C. diphtheriae rpoB and Corynebacterium ulcerans/Corynebacterium pseudotuber-
culosis (CUP) rpoB [37].
Initially, these tests were performed at the Institute of Epidemiology Disease Control and
Research (IEDCR) in Dhaka; from March 2019 onwards, PCR analyses were performed at the
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IEDCR Field Laboratory in Cox’s Bazar Medical College Hospital. Between December 19 and
December 25, 2017, during the peak of the outbreak, a representative subset of cases was tested
to establish the sensitivity of the case definitions, and since June 2018, all suspected and proba-
ble cases were tested.
Contact tracing, prophylaxis, and mass vaccination
Contact tracing was established in mid-December 2017. Close contacts of all probable and
confirmed cases were identified during the case investigation process and targeted for vaccina-
tion, treatment, and follow-up over the course of prophylactic antibiotic treatment. Exposed
contacts were vaccinated according to WHO strategy; pentavalent vaccine was administered
for those aged 6 weeks to 6 years, while tetanus and diphtheria (Td) vaccine was administered
to those aged 7 years and older. One booster dose was administered if documentary evidence
of having completed the primary vaccination schedule was available, otherwise 3 doses were
administered, with at least 4 weeks interval between doses. Further details on the protocol are
reported elsewhere [34].
Different contact tracing and treatment regimen were implemented during 3 periods:
i. Between establishment and February 20, 2018, a 7-day regimen of chemoprophylaxis was
provided to contacts to self-administer, during which time contact tracers visited all con-
tacts 3 times, on days 0, 3, and 7 after their last exposure with the case.
ii. Following a technical consultation among experts in the clinical management of diphtheria,
from February 21 to May 5, 2018, the chemoprophylaxis course was reduced to a 3-day reg-
imen, given to contacts to self-administer daily on days 0, 1, and 2, while contact tracers fol-
lowed-up on days 0 and 3.
iii. Due to concerns about compliance and adherence to treatment, from May 6 onwards, che-
moprophylaxis was provided to contacts by the contact tracers at visits on days 0, 1, and 2,
who directly observed them taking the medication at this time. Contact tracers continued
to make 1 final follow-up visit on day 7.
Pregnant women and children aged 6 weeks to 14 years among the Rohingya and host com-
munity residing in Ukhia and Teknaf Upazilas were targeted for 3 doses of vaccination over 3
rounds of a reactive diphtheria mass vaccination campaign (MVC) during December 12 to 31,
2017, January 27 to February 10, 2018, and March 10 to 25, 2018 [4]. Pentavalent vaccine
against diphtheria, pertussis, tetanus, hepatitis B, and Haemophilus influenzae type b (Hib) was
offered to children aged 6 weeks to 6 years and Td to children aged 7 to 14 years [2]. Adminis-
trative vaccination coverage for all rounds was estimated using vaccine consumption monitor-
ing data collected during the campaigns with population estimates provided by MOH&FW
and the United Nations High Commissioner for Refugees (UNHCR). Individual-level vaccina-
tion coverage was estimated by household survey and reported elsewhere [4].
Statistical analysis
Continuous variables were described as median values with interquartile ranges (IQRs) and
compared by t test or Mann–Whitney U-test. Frequencies for categorical variables were tabu-
lated. The crude overall attack rate was calculated by dividing the total number of diphtheria-
infected Rohingya by the settlement population. An adjusted estimate was made by restricting
the analysis to confirmed and probable cases. We explored missing data for patterns of miss-
ingness and associations between missing and observed data; cases with missing data for vari-
ables of interest were excluded from analyses involving those variables.
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We constructed unadjusted and adjusted multivariable Poisson regression models to iden-
tify risk factors for fatal outcome among confirmed and probable cases, expressed as risk ratios
(RRs). To describe the role of diagnostics in this outbreak, we used Poisson regression to iden-
tify risk factors for testing PCR positive among all individuals tested (i.e., including those non-
cases who tested negative and were excluded from other analyses).
To assess the validity of the probable case definition, we began by evaluating the sensitivity,
specificity, and positive and negative predictive values (PPV and NPV, respectively) of present-
ing with either pseudomembrane or GCL against confirmatory laboratory testing as the refer-
ence. In order to identify practical enhancements for the clinical screening of patients in the
absence of widespread testing, we assessed changes in the performance of the probable case
definition through inclusion of additional signs and symptoms. Finally, we explored risk fac-
tors for presenting with either pseudomembrane or GCL using multivariable Poisson
regression.
To assess the effectiveness of the active case finding and early case isolation response strat-
egy, we calculated time from symptom onset to hospitalization, to which we fitted a multivari-
able linear regression model to identify risk factors for longer delays to presentation [38]. For
response activity evaluations, we bisected the outbreak into 2 phases, corresponding to the
periods before (period 1) and after (period 2) the end of the first round of the MVC (December
31, 2017). For age analyses, we divided cases into 3 age categories at the time of disease onset,
based on vaccination schedule: under 7 years, 7 to 14 years, and 15 years and older. We calcu-
lated confidence intervals (CIs)of proportions assuming binomially distributed symptom
occurrence. CFRs were calculated using observed deaths.
Daily growth rate (r) and epidemic doubling and halving times were estimated by Poisson
regression of the incidence data during the growth and decay phases of the outbreak (bisected
by the date of peak incidence by symptom onset), as implemented in the R package R0 [39,40].
We parameterized the model with a serial interval of mean 4.5 days and standard deviation 6.0
days, derived from published literature [7,41–43]. The initial daily growth rate was used to esti-
mate the initial reproduction ratio (R) [40]. As a sensitivity analysis, we also calculated r and R
during the period that best fit an exponential growth curve, using the deviance R-squared sta-
tistic to automatically select the period [40].
We estimated the time-varying reproduction number (Rt) during the epidemic using dates
of symptom onset, in a Bayesian framework using a Markov chain Monte Carlo approach cal-
culated using a 7-day sliding window, as implemented in the R package EpiEstim [44–46].
Initial analyses were performed in real time to inform the outbreak response activities. An
analysis plan was developed prior to analyzing the final dataset in November 2019 (S1 Analysis
Plan), and no data-driven changes to this analysis took place, except where these informed the
construction of stepwise regression models. All analyses were performed using R (version
4.0.2) [47].
Ethics statement
The formulation of this work was discussed with national health institutes and the civil sur-
geon responsible for the oversight in the activities in the scope of the refugee crisis in Cox’s
Bazar, Bangladesh. The data reported were collected in the course of the public health outbreak
response activity; therefore no additional ethical approval was sought at the time of data collec-
tion. All individual case data were anonymized. This study is reported as per the Strengthening
the Reporting of Observational Studies in Epidemiology (STROBE) guidelines (S1 Checklist).
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Results
Descriptive epidemiology
A total of 7,064 cases with diphtheria were reported among Rohingya (and additional 227
cases were reported among the local Bangladesh population, but these will not be considered
further in this analysis). There were 285 (4.0%) laboratory-confirmed, 3,610 (51.1%) probable,
and 3,169 (44.9%) clinically suspected cases (Table 1, Fig 1), with an additional 1,624 suspected
cases testing negative for diphtheria. The crude diphtheria attack rate over the first 2 years of
the outbreak was 51.5 cases per 10,000 person-years; including only confirmed and probable
cases, the attack rate was 28.4 cases per 10,000 person-years. The median age of cases was 10
years (IQR 7 to 15; range 0 to 85), with those aged under 7 years, 7 to 14 years, and 15 years
and older representing 1,729 (24.5%), 3,309 (46.8%), and 2,026 (28.7%) of cases, respectively
(Table 1). Overall, 3,126 (44.3%) were male. There were marked differences in the sex distribu-
tion between age groups; although the ratio of females to males was approximately equal to 1
(0.98) among children aged under 15 years (2,488 females:2,550 males), that among adult cases
was 2.5 (1,450 females:570 males). Most patients (5,850, 82.8%) recovered, while 45 were
recorded as having died from diphtheria: 2 among confirmed, 19 among probable, and 24
among suspected cases (overall CFR 0.6% with no significant difference by case definition)
(Table 2). A total of 1,075 cases (15.2%) were lost to follow-up (no final outcome recorded) fol-
lowing an initial evaluation. We found no evidence of patterns of missingness or associations
between missing and observed data.
We estimated r as 0.16 per day (95% CI: 0.15 to 0.17) and R as 2.1 (95% CI: 2.0 to 2.1) dur-
ing the period before peak incidence (December 14, 2017). Epidemic doubling and halving
times were calculated as 4.4 days (95% CI 4.2 to 4.7) and 32.9 days (95% CI: 31.9 to 33.9),
respectively (Fig 2A). The sensitivity analysis identified the period best describing exponential
growth as November 13 and December 7, 2017, during which time R was estimated as 3.0
(95% CI 2.8 to 3.3). An additional sensitivity analysis restricted to confirmed and probable
cases only estimated r of 0.11 per day (95% CI: 0.10 to 0.12), R of 1.7 (95% CI: 1.7 to 1.8), and
doubling and halving times of 6.3 days (95% CI 5.9 to 6.8) and 25.6 days (95% CI: 24.6 to 26.7),
respectively.
The MVC launch coincided with a decrease in incidence and transmissibility, as measured
by Rt (Fig 2). As is frequently observed, Rt was high and unstable in the early stage of the epi-
demic when the epidemic was growing exponentially but the overall epidemic size was low,
subsequently decreasing rapidly, crossing the threshold of Rt = 1.0 around the date of peak
Table 1. Characteristics of diphtheria cases by case definition among Rohingya refugees, Cox’s Bazar, Bangladesh, November 10, 2017 to November 10, 2019.
Case definition
Characteristic Confirmed Probable Suspect Total
Age <7 59 873 797 1,729
7–14 136 1,743 1,430 3,309
15–29 83 784 693 1,560
30–44 4 158 170 332
45+ 3 48 77 128
Missing 0 4 2 6
Sex Male 118 1,632 1,376 3,126
Female 167 1,978 1,793 3,938
Total - 285 3,610 3,169 7,064
https://doi.org/10.1371/journal.pmed.1003587.t001
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incidence (Fig 2B). During this initial phase, median Rt was 2.62 (95% CI: 1.95 to 3.57), after
which Rt oscillated around 1 (median Rt = 0.96, 95% CI: 0.71 to 1.30) for an extended period.
Clinical management
The overall median delay from illness onset to examination was 2 days (IQR: 1 to 3, range: 0 to
33 days), decreasing significantly from 2.9 days in period 1 to 2.3 days in period 2 (t(5548) =
10.8, p< 0.001). Overall, one-quarter of cases reported receiving at least 1 dose of diphtheria
toxoid vaccine (1640, 23.2%), increasing markedly from 1.0% in period 1 to 51.1% in period 2.
Of those vaccinated, 524 (32.0%) were vaccinated prior to symptom onset, and 54 (3.3%) were
vaccinated after symptom onset (data missing for 1,062 (64.8%) patients). Details of signs and
symptoms at the time of admission to DTC were available for 6,730 (95.3%) of cases. These
included sore throat (93.5%), fever (86.0%), pseudomembrane (34.7%), difficulty swallowing
(35.1%), and GCL (30.6%) (Table 2). Altogether, 73 (1.0%) of the probable or confirmed cases
reported complications prior to discharge or death; peripheral neuritis/neuropathy (n = 28,
38.4%) and respiratory distress (n = 26, 35.6%) were reported (Table 2). Out of 949 patients for
whom follow-up was done at 30 days post-discharge, 1 patient was recorded as having died
due to an unrelated cause, and one was recorded as having recovered with sequelae (no addi-
tional information recorded).
Antibiotic treatment was received by 4,379 (62.0%) patients: 4,230 (59.9%) received azithro-
mycin, 67 (0.9%) received penicillin, and 3 (0.04%) received erythromycin. A total of 183
Fig 1. Weekly epidemic curve of diphtheria cases (confirmed, probable, and suspected) among Rohingya refugees, Cox’s Bazar, Bangladesh, November 10, 2017
to November 10, 2019.
https://doi.org/10.1371/journal.pmed.1003587.g001
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(2.6%) patients received an unspecified “other” antibiotic, while 220 (3.1%) received a steroid
treatment.
DAT was administered to 1,062 (89.0%) out of 1,193 eligible patients, of whom 1,023
(96.3%) also received antibiotic treatment. No differences in age group or sex were observed
between those DAT-eligible patients who received DAT and those who did not, but patients
presenting during period 1 were less likely than those presenting during period 2 to have been
administered DAT (78.5% versus 92.0%, X2 (1, N = 1044) = 19.0, p< 0.001). Despite protocols
to perform DAT sensitivity tests on all eligible patients prior to administration, this was only
done for 545 (52.3%), of whom 40 (7.3%) were hypersensitive. Adverse reactions following
DAT administration were reported among 229 (21.6%) patients who received DAT, of whom
65 (28.1%) and 4 (1.7%) had febrile and anaphylactic reactions, respectively. As a preventive
measure against side effects, supportive treatment of antihistamine and/or corticosteroids dur-
ing DAT administration was given to 754 (77.5%) of DAT-treated patients.
The median delay from symptom onset to presentation at health facilities was significantly
greater among fatal cases (median delay 4 [IQR 2 to 6] days) compared to survivors (median
delay 2 [IQR 1 to 3] days), p< 0.001, and the risk of dying increased substantially for each
additional day of delay (Table 3). In univariable analyses, confirmed and probable cases aged 0
to 6 years had the greatest risk of death, but there was no association observed for sex. Cases
presenting with respiratory distress (RR = 13.21 [95% CI 4.32 to 33.73]) or pseudomembrane
(RR = 11.76 [95% CI 2.45 to 211.01]) were more likely to be fatal. Cases presenting with GCL
were less likely to be fatal (RR = 0.32 [95% CI 0.11 to 0.79]). Patients who received antibiotic
treatment were less likely to die (RR = 0.38 [95% CI 0.16 to 0.89]); receiving DAT was associ-
ated with a higher risk of death (RR = 3.35 [95% CI 1.02 to 14.93]). No fatal cases were vacci-
nated prior to disease onset. In a multivariable model containing all these explanatory
Table 2. Number (%) of signs and symptoms, complications, and treatment outcomes among diphtheria cases, by case definition, among Rohingya refugees, Cox’s
Bazar, Bangladesh, November 10, 2017 to November 10, 2019.
Characteristic Confirmed (N = 285) Probable (N = 3,610) Suspected (N = 3,169) All cases (N = 7,064)
Sign/symptom Sore throat 282 (98.9) 3,551 (98.4) 2,771 (87.4) 6,604 (93.5)
Fever 259 (90.9) 3,246 (89.9) 2,573 (81.2) 6,078 (86.0)
Pseudomembranes 195 (68.4) 2,258 (62.5) 0 2,453 (34.7)
Difficulty in swallowing 183 (64.2) 1,269 (35.2) 1,026 (32.4) 2,478 (35.1)
Lymphadenopathy 125 (43.9) 2,040 (56.5) 0 2,165 (30.6)
Tonsillitis 45 (15.8) 284 (7.9) 154 (4.9) 483 (6.8)
Nasal regurgitation 15 (5.3) 159 (4.4) 208 (6.6) 382 (5.4)
Nasal blood 13 (4.6) 34 (0.9) 41 (1.3) 88 (1.2)
Lethargy 2 (0.7) 39 (1.1) 45 (1.4) 86 (1.2)
Complications Neuropathy 4 (1.4) 21 (0.6) 3 (0.1) 28 (0.4)
Respiratory distress 3 (1.1) 19 (0.5) 4 (0.1) 26 (0.4)
Cutaneous necrosis 1 (0.4) 2 (0.1) 1 (<0.1) 4 (0.1)
Irregular heart rhythm 0 (0.0) 3 (0.1) 2 (0.1) 5 (0.1)
Shock 0 (0.0) 5 (0.1) 1 (0.1) 6 (0.1)
Kidney damage 0 (0.0) 2 (0.1) 0 (0.0) 2 (<0.1)
Treatment outcomes Recovered 241 (84.6) 3,143 (87.1) 2,466 (77.8) 5,850 (82.8)
Death 2 (0.7) 19 (0.5) 24 (0.8) 45 (0.6)
Transferred 2 (0.7) 53 (1.5) 29 (0.9) 84 (1.2)
Left against medical advice 2 (0.7) 72 (2.0) 106 (3.3) 180 (2.5)
Lost to follow-up 38 (14.0) 317 (8.8) 540 (17.0) 895 (12.7)
Other 0 (0.0) 6 (0.2) 4 (0.1) 10 (0.1)
https://doi.org/10.1371/journal.pmed.1003587.t002
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variables, younger age, respiratory distress, presenting with pseudomembrane, and treatment
with DAT remained strongly associated with higher risk of death, while antibiotic treatment
remained a significant protective factor (Table 3). There was no evidence of an effect on risk of
death of receiving the full “package” of interventions (vaccination and antibiotic treatment
and DAT treatment) versus receiving none of the package (RR = 0.36 [95% CI 0.04 to 3.04]),
but with just 2 deaths in each group, the study was likely underpowered to adequately explore
this relationship.
Diagnostics
Multiplex PCR assay was performed on 1,329 cases, and 271 (20.4%) tested positive for tox-
bearing C. diphtheriae. Additionally, 659 swabs were cultured. Among 705 laboratory-tested
pseudomembrane positive cases, only 215 (30.5%) were PCR positive. Cases aged 15 years and
older were less likely to be laboratory confirmed than younger cases. Cases presenting with a
pseudomembrane or with symptoms onset during the pre-vaccination campaign period were
more likely to be confirmed (Table 4). Owing to very limited laboratory capacity to respond to
Fig 2. a) Poisson models fitted to daily incidence over time, bisected by date of peak incidence (December 14, 2017), Cox’s Bazar, Bangladesh,
November 10, 2017 to July 31, 2018. The timing of 3 rounds of MVC are shown as transparent beige bars. b) Estimates of time-varying reproduction
number (Rt) for diphtheria cases, Cox’s Bazar, Bangladesh, November 10, 2017 to July 31, 2018. The time period was limited to July 31, 2018 owing
to highly unstable estimates of Rt produced thereafter due to the effect of sporadic cases. MVC, mass vaccination campaign.
https://doi.org/10.1371/journal.pmed.1003587.g002
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Table 3. Multivariable Poisson regression for predictors of fatality among for confirmed and probable diphtheria patients, Cox’s Bazar, Bangladesh, November 10,
2017 to November 10, 2019.
Unadjusted Adjusted
Independent variable Level N RR (95% CI) p-value RR (95% CI) p-value
Age group 0–6 932 Reference - Reference -
7–14 1,879 0.02 (0.001–0.003) <0.001 0.11 (0.02–0.53) 0.006
15+ 1,080 0.00 (0.00–Inf) 0.993 0.00 (0.00–Inf) 0.992
Sex Female 2,145 Reference - - -
Male 1,750 0.75 (0.30–1.79) 0.530 - -
Vaccination status Unvaccinated 1,214 Reference - - -
Vaccinated 845 1.08 (0.21–4.89) 0.922 - -
Delay 1 day
�
3,895 1.13 (0.99–1.22) 0.011 1.13 (0.99–1.29) 0.076
Respiratory distress False 3,805 Reference - Reference -
True 90 13.21 (4.32–33.73) <0.001 13.65 (4.59–40.61) <0.001
Pseudomembrane False 1,442 Reference - Reference -
True 2,453 11.76 (2.45–211.01) 0.016 10.85 (1.28–92.27) 0.029
GCL False 1,730 Reference - Reference -
True 2,165 0.32 (0.11–0.79) 0.018 0.50 (0.17–1.47) 0.207
Antibiotic treatment False 1,141 Reference - Reference -
True 2,754 0.38 (0.16–0.89) 0.025 0.22 (0.06–0.76) 0.017
DAT False 980 Reference - Reference -
True 983 3.35 (1.02–14.93) 0.066 5.43 (1.39–21.23) 0.015
� RR for each additional day delay between disease onset and presentation at health facility.
Covariates with a p-value of < = 0.1 were included in the multivariate model.
CI, confidence interval; DAT, diphtheria antitoxin; GCL, gross cervical lymphadenopathy; RR, risk ratio.
https://doi.org/10.1371/journal.pmed.1003587.t003
Table 4. Multivariable Poisson regression for predictors for diphtheria patients testing positive (as opposed to negative) for toxigenic C. diphtheriae strain by PCR,
Cox’s Bazar, Bangladesh, November 10, 2017 to November 10, 2019.
Unadjusted Adjusted
Independent variable Level N RR (95% CI) p-value RR (95% CI) p-value
Age group 0–6 1,942 Reference - Reference -
7–14 3,968 0.88 (0.66–1.19) 0.393 0.95 (0.69–1.32) 0.751
15+ 2,971 0.44 (0.32–0.60) <0.001 0.52 (0.37–0.74) <0.001
Sex Female 5,124 Reference - Reference -
Male 3,764 1.34 (1.07–1.67) 0.011 1.12 (0.88–1.43) 0.361
Vaccination status Unvaccinated 2,097 Reference - - -
Vaccinated 2,211 0.82 (0.61–1.10) 0.177 - -
Period Pre-campaign 3,091 Reference - Reference -
Campaign era
�
5,205 0.41 (0.32–0.55) <0.001 0.63 (0.47–0.84) 0.001
Pseudomembrane False 5,856 Reference - Reference -
True 2,981 3.93 (3.11–4.99) <0.001 3.78 (2.95–4.88) <0.001
GCL False 5,820 Reference - - -
True 3,017 0.91 (0.73–1.14) 0.443 - -
� Patients were divided into 2 periods, according to the date of symptom onset relative to the completion of the first round of MVC.
Patients not tested or those with indeterminate results were excluded.
Covariates with a p-value of < = 0.1 were included in the multivariate model.
CI, confidence interval; GCL, gross cervical lymphadenopathy; MVC, mass vaccination campaign; RR, risk ratio.
https://doi.org/10.1371/journal.pmed.1003587.t004
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the large demand at the time, cases that tested diphtheria negative were not investigated
further.
The probable case definition—presenting with pseudomembrane or GCL—was 83.9% sen-
sitive and 34.4% specific, with 19.3% PPV and 91.9% NPV (Table 5). Sensitivity was enhanced
by the addition of either sore throat (99.2%) or fever (98.4%) to this case definition, although
specificity was greatly reduced as a result. Conversely, specificity was enhanced by the addition
of nasal regurgitation (93.3%), lethargy (98.1%), or nasal blood (98.5%), the latter also provid-
ing the most balanced performance in terms of PPV (70.9%) and NPV (86.8%).
The risk of presenting with pseudomembrane was greater among children aged 7 to 14
years (RR = 1.42 [95% CI 1.19 to 1.71]) and among adults aged 15 years or older (RR = 1.66
[95% CI 1.38 to 2.02]) (compared to children aged under 7 years) and lower among vaccinated
cases (with a dose response such that risk was lowest among those having received all 3 doses,
RR = 0.64 (95% CI 0.50 to 0.82]) and patients with symptom onset during period 2 (RR = 0.54
[95% CI 0.45 to 0.65]) (Table 6). There was no association observed between sex of the patient
Table 5. Sensitivity, specificity, PPV, and NPV of an enhanced probable case definition (presence of either PM and/or GCL) with inclusion of additional signs and
symptoms, Cox’s Bazar, Bangladesh, November 10, 2017 to November 10, 2019.
Additional sign/symptom n (N = 2006) Sensitivity (%) Specificity (%) PPV (%) NPV (%)
None (PM and/or GCL alone) 1,373 83.9 34.4 19.3 91.9
Sore throat 1,367 99.2 0.5 15.7 79.3
Fever 1,304 98.4 1 15.7 76.9
Difficulty in swallowing 1,136 87.9 8.2 15.2 78.4
Tonsillitis 396 48.4 59.3 18.2 86
Nasal regurgitation 52 20.3 93.3 36.1 86.2
Nasal blood 21 20 98.5 70.9 86.8
Lethargy 13 3.8 98.1 27.7 84.5
GCL, gross cervical lymphadenopathy; NPV, negative predictive value; PM, pseudomembrane; PPV, positive predictive value.
https://doi.org/10.1371/journal.pmed.1003587.t005
Table 6. Multivariable Poisson regression for risk factors for diphtheria patients presenting with pseudomembrane and lymphadenopathy, Cox’s Bazar, Bangla-
desh, November 10, 2017 to November 10, 2019.
Presence of pseudomembrane Presence of GCL
Unadjusted Adjusted Unadjusted Adjusted
Independent variable Level N RR (95% CI) p-value RR (95% CI) p-value RR (95% CI) p-value RR (95% CI) p-value
Age group 0–6 1,729 Reference - Reference - Reference - Reference -
7–14 3,309 1.28 (1.15–1.42) <0.001 1.42 (1.19–1.71) <0.001 0.93 (0.84–1.03) 0.165 0.96 (0.85–1.10) 0.569
15+ 2,020 1.42 (1.27–1.59) <0.001 1.66 (1.38–2.02) <0.001 0.71 (0.63–0.80) <0.001 0.69 (0.59–0.80) <0.001
Sex Female 3,938 Reference - - - Reference - Reference -
Male 3,126 0.93 (0.86–1.01) 0.100 - - 1.16 (1.07–1.27) <0.001 1.11 (1.00–1.24) 0.052
Vaccination doses 0 (ref.) 1,876 Reference - Reference - Reference - Reference -
1 510 0.67 (0.55–0.81) <0.001 0.77 (0.62–0.94) 0.013 1.00 (0.86–1.15) 1.000 0.99 (0.85–1.16) 0.947
2 493 0.72 (0.59–0.87) 0.001 0.87 (0.71–1.06) 0.172 1.06 (0.91–1.22) 0.452 1.00 (0.85–1.16) 0.962
3 382 0.54 (0.42–0.68) <0.001 0.64 (0.50–0.82) 0.001 0.71 (0.58–0.85) <0.001 0.68 (0.56–0.83) <0.001
Period Pre-campaign 2,927 Reference - Reference - Reference - Reference -
Campaign era
�
3,617 0.77 (0.71–0.83) <0.001 0.54 (0.45–0.65) <0.001 2.27 (2.06–2.51) <0.001 0.79 (0.66–0.93) 0.006
� Patients were divided into 2 periods, according to the date of symptom onset relative to the completion of the first round of MVC.
Covariates with a p-value of < = 0.1 were included in the multivariate model.
CI, confidence interval; GCL, gross cervical lymphadenopathy; MVC, mass vaccination campaign; RR, risk ratio.
https://doi.org/10.1371/journal.pmed.1003587.t006
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and presenting with pseudomembrane. By contrast, the risk of presenting with GCL was
greater among children aged under 7 years, and among males (RR = 1.11 [95% CI 1.00 to
1.24]), but as with pseudomembrane, the risk was lowest among vaccinated cases having
received all 3 doses (RR = 0.68 (95% CI 0.56 to 0.83]) and those presenting during period 2
(RR = 0.79 (95% CI 0.66 to 0.93]).
Contact tracing, prophylaxis, and reactive and mass vaccination
Household contacts for 5,702 (80.7%) of 7,064 cases were successfully traced. A total of 41,452
contacts were identified (median 5 contacts per case, range 0 to 49), of whom 40,364 (97.4%)
consented to begin chemoprophylaxis; adherence was 55.0% (N = 22,218) at 3-day follow-up.
The proportion of household contacts vaccinated was 64.7% overall. The administrative cover-
age of the MVC was 88.5%, 110.4%, and 104.0% for the first, second, and third rounds, respec-




To our knowledge, this outbreak was the largest reported diphtheria outbreak occurring
among refugees. It reflects a long history of under-provision of health services to the Rohingya
in Rakhine state, including routine vaccinations. Very low vaccination coverage, high popula-
tion density, and poor living conditions were associated with a doubling time of around 4 days
was observed, with explosive expansion of the outbreak during the initial exponential growth
phase. Our findings suggest that 3 rounds of mass vaccinations targeting all individuals aged 6
weeks to 14 years and pregnant women in the affected areas may have contributed to reducing
transmission, but alone were not sufficient to end the outbreak. Indeed, this outbreak had a
long-lasting tail, with Rt oscillating at around 1 for an extended period of time. Cases continue
to appear with case clusters still occurring, likely reflecting the lack of universal vaccination
coverage [4,48], which may enable transmission to continue [11,49]. Concurrent diphtheria
outbreaks in Yemen, Indonesia, Venezuela, and Haiti led to shortages of DAT availability glob-
ally [7,32,50], potentially further hampering the outbreak response.
Approximately half of the cases were probable, with only a small fraction of cases test posi-
tive. Overall, two-thirds of the cases were children <15 years of age. The age distribution, with
older cases than expected for a disease that typically affects young children [19], likely reflects
low diphtheria vaccination coverage in this population, or waning immunity, especially
among adults. Similar findings have been reported for diphtheria [51,52] and measles [53,54]
among refugees and other populations lacking adequate routine vaccine coverage. The female
predominance among adults might reflect the practice of nursing of small infants by female
household members—a similar effect was observed in a large outbreak in the former Soviet
Union [33]—but may also reflect health-seeking behavior or the demographic structure of the
refugee population. The majority of Rohingya cases (90%) reported to be unvaccinated, consis-
tent with other recent diphtheria outbreaks reported from South Africa [55], Lao People’s
Democratic Republic [28], Nigeria [22], and Colombia [26]). The clinical presentation of the
cases in the current outbreak was typical of diphtheria [56], yet the mortality was low. Immedi-
ate complications were rare.
While penicillin or erythromycin are recommended for treatment, oral azithromycin, usu-
ally reserved for penicillin-sensitive patients [57], was the most frequently used antibiotic; oral
azithromycin is a once daily dose, which was judged more feasible in this limited resource set-
ting than oral penicillin and erythromycin, which require administration up to 4 times daily.
PLOS MEDICINE Diphtheria outbreak among Rohingya population, Bangladesh 2017-2019
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003587 April 1, 2021 14 / 22
This did not appear to have a negative impact on clinical outcomes; indeed, we observed a low
CFR, and low clinical severity in general, during this outbreak relative to those previously
described [43]. One explanation could be a combination of the following:
1. the implementation of an active case finding strategy leading to shorter delays between dis-
ease onset and presentation and higher reporting rates among mild cases; and
2. effective treatment provided by the national and international healthcare professionals
surged to respond to this outbreak [58,59].
The deaths occurred more commonly among children, and longer delays between onset
and admission were associated with increased risk of death, highlighting the importance of
adequate medical attention in the initial stages of diphtheria. The low observed CFR may also
partially be due to low PPV of the case definitions, such that a substantial proportion of cases
may in fact have been diseases with similar clinical presentation to diphtheria, e.g., bacterial
tonsillitis. Our finding that presenting with GCL was associated with a lower risk of death sug-
gests that this clinical sign, used in the probable case definition, may have been frequently mis-
diagnosed or associated with other less severe diseases. However, as low CFR was also
observed among confirmed and probable cases, another possible explanation is co-circulation
of less virulent isolates of diphtheria [57] and of diphtheria-like illness (which might have led
to extensive false-positive probable case classification). Such information was unavailable here,
and this lack of real-time information on the genotypes of the outbreak strains, the value of
which has been demonstrated elsewhere [60], was identified to be limiting a comprehensive
understanding of the disease in this particular setting [61].
The risk of presenting with pseudomembrane and GCL was greater among those detected
during period 1, indicating either under-ascertainment of mild cases during the early phase of
the epidemic, decreased severity post-vaccination, or that the case definition was implicitly
expanded by clinicians to be more sensitive and less specific during the later periods of low
incidence.
Respiratory distress and treatment with DAT were associated with greater risk of death,
presumably reflecting more severe disease among these patients. Antimicrobial treatment was
associated with a lower risk of death, suggesting it was an effective treatment.
We estimated the basic reproduction number R0 during the exponential growth phase at
3.0, which approximates to that reported in a pooled analysis of previous outbreaks of diphthe-
ria of 2.7 [95% CI 1.7 to 4.3] [43]. The findings that both transmissibility and the delay from
disease onset to presentation at health facilities decreased during the early phase of this out-
break suggest that implemented interventions, specifically contact tracing, active case finding,
and early isolation of cases, were effective. The high vaccination campaign coverage rates
reflected high overall vaccination campaign coverage estimates of 93% for 1 dose and 89% for
2 doses, as reported in a vaccination coverage and seroprevalence survey conducted approxi-
mately 1 month after the final round of the vaccination campaign [4]. However, this declined
to just 77% for a third dose.
Strengths and limitations
Lack of adequate diagnostic capacity was a major limitation of this study, with a majority of
cases unconfirmed and no clear understanding of the range of co-circulating diphtheria-like
illnesses. Therefore, the proportion of true diphtheria cases remained unknown, potentially
biasing the results. Additionally, the tox+ isolates were not systematically tested using Elek test
for the production of toxin, which would have informed the understanding of the circulating
strains and their toxicity and the extent of misdiagnosis. Introduction of standardized case
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report forms, implementation of the EWARS-in-a-box system, and extensive retrospective
chart review largely resolved data quality concerns. The limitations on beds, staff, DAT, vac-
cine, and antibiotic supply on-site potentially hampered control efforts during this outbreak.
Despite these limitations, our analyses were informed by a large study sample size due to the
unprecedented size of the outbreak. This article may provide a generalizable description of
diphtheria outbreaks, especially under crowded and inadequate hygienic conditions.
Implications for further research, clinical practice, and public
policy
Only approximately 20% of those tested for diphtheria tested positive in this population. As a
large majority of pseudomembrane-positive cases (considered diagnostically highly accurate
of diphtheria infection) tested negative, the validity of the test and sampling procedure should
be evaluated. The diphtheria toxin gene target in the PCR used is sensitive to approximately 10
genome copies per reaction, while the rpoB targets for C. diphtheriae and C. ulcerans/C.
pseudotuberculosis are somewhat less sensitive, between 10 and 100 genome copies per reac-
tion [37]. While clinical validation is unavailable to provide sensitivity data in detail, this PCR
assay was reported to be more sensitive than a previous assay during an analysis of 105 clinical
samples [37]. False-negative test results may have arisen if specimen quality was poor, if there
were delays in testing, or if patients received antibiotics (as contacts or for treatment) prior to
testing [62]. Ultimately, the low proportion of cases receiving a diagnostic test and co-circula-
tion of illnesses that resemble diphtheria indicates the need for improvement in alternative
diagnostics and categorization of suspect cases, including the use of mobile and local labora-
tory capacity and deployment of rapid diagnostics tests for diphtheria. Our evaluation of the
validity of the probable case definition (presence of pseudomembrane or GCL) suggested that
it was relatively high in sensitivity but quite unspecific, with high NPV but low PPV. This is
perhaps unsurprising, as other clinical signs are easily mistaken for these classic diphtheria
signs, particularly given the relative rarity of diphtheria under normal circumstances. The
inclusion of additional signs and symptoms when screening on clinical presentation may serve
to enhance the robustness of this procedure. This is particularly true in settings where wide-
spread testing is not available and when a maximally sensitive screening case definition is
desired, for example, during the latter stages of an outbreak in resource-poor settings.
Prior research has suggested that vaccination reduces diphtheria transmission by approxi-
mately 60%, which, when coupled with antibiotic treatment of symptomatic cases, can be
enough to end an outbreak. However, in a population in which R0 is approximately 3.0, con-
trol can only be achieved with treatment of at least half of all symptomatic cases within 2 days
of symptom onset in a fully immunized population [43]. The authors further suggest that
among this population, more than three-quarters (78%) of symptomatic cases would need to
be isolated and treated to end transmission and that a more feasible and effective strategy
would be to instigate random, mass antibiotic administration. Meanwhile, improved delivery
through routine vaccination and enhanced community engagement to address the various
barriers to vaccination have been identified as key approaches to strengthen vaccine demand
and acceptance among this population [63].
The observed decline in incidence after the end of the first round of the MVC suggests a
possible role in vaccine-derived immunity in reducing transmission. However, while the rec-
ognized regimen for diphtheria vaccination requires at least a 6-month interval between the
second and third doses in order to mount durable protection [15], there was just a 1-month
delay between rounds 2 and 3 of the MVC in this setting. This may account for lower estimates
of seroprotection at the�0.1 IU/mL cutoff (63% among 1 to 6 year olds and 77% among 7 to
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14 year olds) than the reported vaccination coverage [4]. This might, in turn, explain the fail-
ure to completely interrupt transmission and eliminate the epidemic in the months following
the vaccination campaign, with Rt oscillating at around 1 from January 2018 onwards. The
remaining case clusters indicate that the interventions appear to have been insufficiently effec-
tive to interrupt transmission and eliminate the outbreak, further supported by the observed
constant proportion of cases testing diphtheria positive.
There may be a need for earlier launching of the MVC with an expanded (older) target age
group given the unusual age distribution of cases observed during this outbreak and its continu-
ation despite the MVC. Consideration may also need to be given to shorter timings between
doses coupled with additional rounds of campaign to address remaining gaps in immunity and
possibly replacing the Td vaccine used among adults with a vaccine containing a higher dose of
diphtheria toxoid. Enhanced detection and isolation of new cases by active case finding using
community health workers, and more effective contact tracing, with possibly a greater propor-
tion of contacts vaccinated and provided with prophylactic antibiotics, might have brought the
epidemic to an earlier end. We found that vaccinated cases had a longer average delay from dis-
ease onset to presentation at health facilities, possibly as a result of reduced severity among vac-
cinated individuals, or of different health-seeking behavior among older individuals.
The limited global supply of both vaccine [50] and DAT [64,65] was an important consider-
ation during this outbreak, particularly as there were multiple concurrent outbreaks. Although
further details are not available, anecdotal reports suggest that the principal reason for those
DAT-eligible patients not receiving DAT was concerns about access to a sustainable DAT sup-
ply, which led some healthcare providers to be more cautious with its administration, particu-
larly during the peak of the epidemic. Although DAT is listed in WHO Model List of Essential
Medicines [66], global access is increasingly difficult due to limited supply and decreasing
demand, which has accompanied increasing vaccination coverage and an accompanying
declining global incidence [57]. The Ad hoc working group for Diphtheria Antitoxin (DAT)
was convened in November 2017 [67] and advocated and managed an increased global stock-
pile of DAT. Our findings support the need for an enhanced global supply of DAT, and further
research to explore the feasibility and efficacy of treatment using reduced amounts of DAT, in
light of the high proportion of side effects observed.
Conclusions
This outbreak reminds us that diphtheria may still cause large, rapidly expanding outbreaks
among susceptible populations in the vaccine era. An adequate global DAT stockpile needs to
be maintained by an independent body, as for yellow fever, meningitis, and cholera vaccines
[68]. Crisis-affected populations must have access to health services, including routine vaccina-
tion. The international community should advocate for these rights among neglected people,
including the Rohingya population residing both in Myanmar and in Bangladesh.
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